SYNTIS BIO

Website

SYNTIS BIO, INC.

9 Investors
Biotechnology (Oral Therapeutics)
Boston, MA

Syntis Bio, Inc. is a pioneering biotechnology company focused on transforming oral therapeutics through innovative solutions targeting the small intestine. By leveraging its proprietary SYNT™ platform, the company enhances the absorption and effectiveness of treatments for prevalent and challenging conditions such as obesity, diabetes, and rare diseases.

Products & Team

SYNT-101

Oral Therapeutic PlatformSeed

SYNT-101 is an innovative oral pill designed to adjust the small intestine's role in metabolism, mimicking the effects of gastric bypass surgery to aid in weight loss management.

Value Proposition

SYNT-101 solves the problem of inadequate drug absorption and effectiveness for conditions driven by metabolic dysfunction.

Pain Points

Ineffective absorption and delivery of oral medications in the small intestine, affecting therapy outcomes

Temporary gastrointestinal coatingActive for up to 24 hours70% glucose blocking20 times improved enzyme activityIncreases oral drug bioavailability by 4-10 times

Rahul Dhanda

Company Signatory
Chief Executive Officerat SYNTIS BIO, INC.
Joined SYNTIS BIO, INC.
January 2025
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
Boston, MA
Primary headquarters

Funding History

Total Raised:
$6.3M
E

Equity, Option to Acquire Offering

December 2024
$9.0M
Target
Progress
70%
Raised
$6.3M
Target
$9.0M
#000194306125000001